157 related articles for article (PubMed ID: 10174467)
1. Comparative experience in home care and pharmaceutical policy.
Kane NM; Saltman RB
Health Policy; 1997 Sep; 41 Suppl():S1-7. PubMed ID: 10174467
[No Abstract] [Full Text] [Related]
2. The effects of copayments and generic substitution on the use and costs of prescription drugs.
Smith DG
Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
[TBL] [Abstract][Full Text] [Related]
3. Health care reform: is the process the outcome?
Gibson E; Lyles A
Clin Ther; 2009 Sep; 31(9):2014-7. PubMed ID: 19843491
[No Abstract] [Full Text] [Related]
4. Medicaid prescription drug coverage: state efforts to control costs.
Gencarelli DM
NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
[TBL] [Abstract][Full Text] [Related]
5. The management of the cost and utilisation of pharmaceuticals in the United Kingdom.
Burstall ML
Health Policy; 1997 Sep; 41 Suppl():S27-43. PubMed ID: 10174472
[TBL] [Abstract][Full Text] [Related]
6. Valuable information regarding generic drugs. Cutting costs by going generic.
J Am Vet Med Assoc; 2004 Oct; 225(8):1168. PubMed ID: 15521435
[No Abstract] [Full Text] [Related]
7. The rising utilization and costs of prescription drugs.
PHC4 FYI; 2004; (26):1-2. PubMed ID: 15344277
[No Abstract] [Full Text] [Related]
8. Pharmaceutical cost containment and innovation in the United States.
Kane NM
Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
[TBL] [Abstract][Full Text] [Related]
9. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
Gross DJ; Ratner J; Perez J; Glavin SL
Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
[TBL] [Abstract][Full Text] [Related]
10. Cost-sharing for prescription drugs.
Gibson TB; McLaughlin CG; Smith DG
JAMA; 2001 May; 285(18):2328-9. PubMed ID: 11343477
[No Abstract] [Full Text] [Related]
11. Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology.
Nguyen HP; Go JA; Barbieri JS; Stough D; Stoff BK; Forman HP; Bolognia JL; Albrecht J;
J Am Acad Dermatol; 2020 Aug; 83(2):691-699. PubMed ID: 32330637
[No Abstract] [Full Text] [Related]
12. Management of cost and utilization of pharmaceuticals in Germany.
von der Schulenburg JM
Health Policy; 1997 Sep; 41 Suppl():S45-53. PubMed ID: 10174473
[TBL] [Abstract][Full Text] [Related]
13. Recent economic trends in American pharmacy.
Schondelmeyer SW
Pharm Hist; 2009; 51(3):103-27. PubMed ID: 20527204
[No Abstract] [Full Text] [Related]
14. Health economics in primary care in the UK: containment of drug costs.
Walley T; Edwards RT
Pharmacoeconomics; 1993 Feb; 3(2):100-6. PubMed ID: 10146959
[No Abstract] [Full Text] [Related]
15. [Economic drug prescription].
Engelbrecht N; Gramkow M
Ugeskr Laeger; 2003 Dec; 165(50):4871-2. PubMed ID: 14716910
[No Abstract] [Full Text] [Related]
16. Cost and utilisation of pharmaceuticals in Sweden.
Ljungkvist MO; Andersson D; Gunnarsson B
Health Policy; 1997 Sep; 41 Suppl():S55-69. PubMed ID: 10174474
[TBL] [Abstract][Full Text] [Related]
17. Cost sharing, caps on benefits, and the chronically ill--a policy mismatch.
Thorpe KE
N Engl J Med; 2006 Jun; 354(22):2385-6. PubMed ID: 16738277
[No Abstract] [Full Text] [Related]
18. Lowering the cost of prescription drugs.
Jindal B
J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
[No Abstract] [Full Text] [Related]
19. Study examines weapons in fight to control drug costs.
Capitation Rates Data; 2001 Apr; 6(4):39-42. PubMed ID: 11330005
[No Abstract] [Full Text] [Related]
20. Pharmacy Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing.
Bai G; Sen AP; Anderson GF
Ann Intern Med; 2018 Mar; 168(6):436-437. PubMed ID: 29435565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
